港交所(00388.HK)與香港科技園於生物科技及金融科技領域合作
香港交易所(00388.HK)宣布與香港科技園公司簽訂合作備忘錄,探索雙方在生物科技及金融科技範疇的合作,推動香港以至亞洲長遠發展成匯聚全球頂尖生物科技及新經濟企業的創科中心。
根據合作備忘錄,香港交易所可借助香港科技園眾多的生物科技行業專家,就生物科技公司的上市申請給予意見。香港科技園將籌組專家團隊,在有需要時與香港交易所分享相關知識及專業意見,協助香港上市制度維持高度投資者保障,鞏固香港作為全球第二大生物科技融資中心的領導地位。
而香港交易所與香港科技園今天簽訂的合作備忘錄除涉及生物科技專業知識共享外,亦會研究開發數據分析平台等其他合作機會。(el/w) ~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.